Figure 1.
Onco-GPS defined 5 NMF components, which clustered into 5 patient groups with distinct DNAm states. (A) NMF component amplitudes (rows) are plotted for each patient (columns) by methylation cluster membership. (B) A 2-dimensional Onco-GPS map is created based on the NMF components, where each patient is represented by an individual colored dot, and each dot’s location is determined by a 2-dimensional projection of the patient’s 5 component amplitudes. (C) Five methylation clusters categorize patients (columns) with distinct genetic and cytogenetic abnormalities (rows). (D) Odds ratio of enrichment for patients with particular genetic lesions within each methylation cluster. Significantly enriched lesions (P < .05) are highlighted in color.

Onco-GPS defined 5 NMF components, which clustered into 5 patient groups with distinct DNAm states. (A) NMF component amplitudes (rows) are plotted for each patient (columns) by methylation cluster membership. (B) A 2-dimensional Onco-GPS map is created based on the NMF components, where each patient is represented by an individual colored dot, and each dot’s location is determined by a 2-dimensional projection of the patient’s 5 component amplitudes. (C) Five methylation clusters categorize patients (columns) with distinct genetic and cytogenetic abnormalities (rows). (D) Odds ratio of enrichment for patients with particular genetic lesions within each methylation cluster. Significantly enriched lesions (P < .05) are highlighted in color.

Close Modal

or Create an Account

Close Modal
Close Modal